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context: Ultrasound (US)-guided percutaneous ethanol injection (PEI) has been pro-
posed for treatment of benign thyroid nodules (TNs). However, there is no consensus for 
the optimal amount of ethanol injection, number of applications, and time to re-evaluation 
in order to achieve maximum volume reduction with minimum adverse effects.
Objective: The purpose of the present study was to analyze the effectiveness of an 
US-guided PEI protocol to treat solid and mixed TNs based on a new target outcome.
Patients and methods: We performed a prospective study evaluating the results of 
PEI in 52 patients with benign solid and mixed TNs. The ethanol dose was fixed in 30% 
of the nodular volume per session. Patients returned 1 month after each session for US 
re-evaluation. Therapeutic success was defined as volume reduction of at least 30% 
associated with disappearance of clinical symptoms and a complete esthetic satisfac-
tion reported by the patient.
results: We performed a mean of 2.8 ± 1.9 PEI sessions, with an average total volume 
of ethanol injected of 9.1 ± 10.3 ml, and a follow-up time of 10.0 ± 8.7 months. There 
was a reduction of at least 50% of the initial nodular volume in 33 patients (63.5%). In 
11 patients (21.2%), the reduction did not reach 50% (mean reduction of 31 ± 11%), 
but 6 of them reported esthetically satisfactory results and treatment was stopped. Our 
therapeutic success rate considering the patients with esthetic improvement was 75%. 
There were no severe complications.
conclusion: Our protocol is effective and safe to treat solid and mixed benign TNs 
based on our established outcome.
Keywords: thyroid nodules, percutaneous ethanol injection, alcoholization, Us-guided, nodule volume reduction
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inTrODUcTiOn
Thyroid nodules (TNs) are common entities, often detected in 
clinical practice, with a largely variable prevalence, depending on 
the diagnostic method (1, 2). Epidemiological studies have shown 
that 4–7% of women and 1% of men living in iodine-sufficient 
regions present palpable TNs (3, 4), whereas ultrasound (US) 
detects nodules in up to 76% of the adult population, with a 
greater incidence in women and elderly people (5–9).
Most TNs are benign (94–96%) (10, 11) small and remain 
asymptomatic, being usually managed only by observation and 
follow-up. A proportion of them, however, may lead to local 
compressive symptoms or esthetic complaints, due to significant 
enlargement, requiring specific intervention (1, 12). The best treat-
ment for benign nodules remains uncertain (13). Alternatively to 
thyroidectomy, the use of non-surgical, image-guided, minimally 
invasive methods has been proposed (12–14), such as US-guided 
percutaneous ethanol injection (PEI) (15, 16).
This method has been suggested to be an effective, safe, and 
inexpensive outpatient procedure for the treatment of benign 
TNs, leading to reduction of nodular volume, with a low rate of 
early and late clinical complications (3, 17–29). It has been rec-
ommended as the first-line therapy of symptomatic and recurrent 
thyroid cysts with benign cytology (30), and may also be used in 
solid nodules, particularly in case of contraindication to or refusal 
of surgery and radioiodine therapy (2, 31–34). However, a stand-
ard US-guided PEI protocol is yet to be established, since there is 
no consensus definition for the optimal amount of ethanol to be 
injected, the number of applications, and the intervals between 
sessions in order to achieve maximum volume reduction with 
minimum adverse effects.
Most articles in literature have considered a nodule volume 
reduction of at least 50% as a partial success and more than 90% 
as a complete outcome (34). It is well known that an established 
benign thyroid nodule rarely becomes too malignant during 
the lifelong (35). Therefore, it makes more sense to evaluate the 
treatment success of this pathology based on disappearance of 
clinical symptoms and a complete esthetic satisfaction to stop PEI 
applications, independently of volume percent reduction. Our 
protocol was based mainly on this idea.
Therefore, the purpose of the present study was to analyze 
the effectiveness of an US-guided PEI protocol to treat solid and 
mixed TNs based on that concept of treatment outcome.
MaTerials anD MeThODs
study Design and Patients
We performed a prospective study evaluating the results of an 
original US-guided PEI protocol in patients with solid and mixed 
TNs at Endocrinology Department of Federal University of Pará, 
from January 2011 to January 2016. We included 52 patients 
diagnosed with TNs and normal thyroid function, confirmed 
to be benign by fine-needle aspiration biopsy (FNAB). Mixed 
TNs were only included when the solid component was >50% 
of the nodular volume. All patients presented compressive local 
symptoms and/or esthetic complaints. Exclusion criteria were 
the presence of malignancy or suspected malignancy detected 
by FNAB. Cystics and autonomous TNs were not included. The 
study was approved by the local ethics committee-University 
Hospital João de Barros Barreto, Federal University of Pará.
Ultrasound-guided Percutaneous 
ethanol injection
Patients were placed in a supine position with mild neck exten-
sion. After skin sterilization, a 22 gage needle (Becton Dickinson 
30 × 7) was inserted through the epidermis to the thyroid pericap-
sular space under US guidance, reaching the center of the target 
lesion. Then, 99% ethanol was slowly instilled into the nodule, 
respecting the patient’s tolerance. Ethanol diffusion through the 
lesion was monitored as intense echogenicity in real-time obser-
vation by US. The procedure was stopped if ethanol leaked out 
of the nodule or if the patient complained of severe pain. None 
of 52 patients were dropped out through this procedure, and no 
cases of severe pain were reported. The procedure was carried out 
without local anesthesia at the puncture site.
The amount of ethanol injected was equivalent to approxi-
mately 30% of the nodule volume, estimated by ultrasonography 
before each application. The nodular volume (milliliter) was 
obtained by multiplying the product of the longitudinal, lateral, 
and anteroposterior axes (centimeter) by the constant 0.52.
In mixed nodules, we removed the liquid portion guided 
for the US, and the nodular volume was calculated. In cases of 
septated nodules, the greatest possible liquid part was removed. 
If  patients had a multinodular goiter, treatment was only per-
formed in the dominant nodule. In all alcoholization sessions, 
the amount of injected ethanol did not exceed 5 ml.
Nodular volume reduction was calculated according to the 
following formula: [Pretreatment volume (milliliter)  −  Post-
treatment volume (milliliter)]  ×  100%/Pretreatment volume 
( milliliter). The PEI sessions were followed by monthly assess-
ments of nodular volume by US, and clinical evaluation.
Therapeutic success was defined as volume reduction of at 
least 30% associated with disappearance of clinical symptoms 
and a complete esthetic satisfaction reported by the patient. The 
procedure was considered ineffective when the nodule did not 
show significant volume reduction (30%) and the patient did not 
refer esthetic improvement after at least three sessions of PEI and 
a follow-up period of at least 6 months.
The new information of our study is a protocol that used 
ethanol fixed doses, but with shorter periods of re-evaluation 
by US and consequently more frequent applications based not 
just in nodule volume. We have also taking in consideration 
the disappearance of clinical symptoms and a complete esthetic 
satisfaction to stop PEI applications.
statistical analysis
Categorical variables were presented as frequency (percentage). 
All normally distributed values were given as mean ±  SD and 
all other values were given as median (range). The Wilcoxon test 
was applied to compare thyroid nodules initial and final volumes. 
A two-sided p < 0.05 was considered statistically significant. Data 
were analyzed using Sigma Stat version 3.5 (Jandel Scientific 
Corporation, Chicago, IL, USA) and Statistical Package for the 
Social Sciences version 21.0 (IBM, Chicago, IL, USA).
TaBle 1 | Us evaluation of the thyroid nodules before and after treatment 
(n = 52).
Variables Mean ± sD
Initial volume (cm3)* 13.2 ± 12.5
Final volume (cm3) 7.1 ± 9.9
Volume reduction (cm3) 6.2 ± 8.2
Volume reduction (%) 44.5 ± 47.4
Number of US evaluations 5.0 ± 2.7
*p < 0.01 vs. final volume.
TaBle 2 | Outcomes of Us-guided Pei for treatment thyroid nodules.
reference country number of 
nodules
Type of nodule Volume of ethanol  
injected (mean ± sD)
number of sessions 
(mean ± sD)
Therapy  
success (%)
Follow-up 
(months)
This research Brazil 52 Mixed and solid 9.1 ± 10.3 ml (total) 2.8 ± 1.9 75 10 months
Perez et al. (2) Brazil 120 Cystic, mixed, solid, 
and autonomous
6.2 ml (total) 2.8 70 6 months–11 years
Basu et al. (36) India 60 Cystic and mixed NA NA 78 12.3 months
Kim et al. (33) South 
Korea
30 Solid 2.3 ml (first session) 1.2 60 15 months
Tarantino et al. (32) Italy 124 Cystic, mixed, and solid 14 ml (total) 4 66 60 months
Del Prete et al. (37) Italy 98 Cystic NA NA 94 9 years
Cho et al. (38) South 
Korea
22 Cystic and mixed NA 1.2 68 3.5 months
Zingrillo et al. (39) Italy 43 Cystic NA NA 93 5 years
Yasuda et al. (40) Japan 61 Cystic and mixed NA 1.26 72.1 1–6 months
Bianchini et al. (41) Brazil 26 Solid 10 ml 5 74 12 months
Lee et al. (34) South 
Korea
198 Solid NA 2.2 ± 1.4 89 36.2 months
NA, not available.
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resUlTs
Our study group consisted of 51 women (98%) and 1 man, with 
a mean age of 45.2 ± 16.6 years. Among TNs, 19 (36, 5%) were 
mixed and 33 (63, 5%) solid.
We performed a mean of 2.8 ±  1.9 PEI sessions, with an 
average total volume of ethanol injected of 9.1 ±  10.3  ml, and 
a follow-up time of 10.0 ±  8.7 months. Data regarding the US 
evaluation of the TNs before and after treatment are described 
in Table 1. There was a reduction of at least 50% of the initial 
nodular volume in 33 patients (63, 5%). In 11 patients (21, 2%), 
the reduction did not reach 50% (mean reduction of 31 ± 11%). 
In eight patients (15, 3%), the nodular volume either increased or 
remained unchanged.
Additionally, 6 of the 11 patients who did not achieve 50% 
of nodular volume reduction reported esthetically satisfactory 
results with a reduction of 30–50%, continuing in the protocol 
with only clinical follow-up. Considering all patients with nodular 
volume reduction ≥50% (n = 33) and those who reported esthetic 
improvement with reduction of 30–50% (n = 6), the therapeutic 
success rate of our PEI protocol increases to 75% (39/52). We 
compared our results with other series using PEI for treating TNs 
(Table 2).
Complications associated with PEI were reported in two 
patients, and included one hematoma with full recovery during 
the follow-up period. Some patients complained of local pain 
at the injection site. However, pain was mild and transient, and 
there were no severe complications, such as massive hemorrhage, 
vocal cord paralysis, or transient thyrotoxicosis.
DiscUssiOn
In the present study, we realized an US-guided PEI protocol for 
the treatment of benign mixed and solid TNs, with a 75% success 
rate in a short follow-up period. The procedure was safety in 
comparison to other methodologies previously described.
The use of USG-guided PEI as an alternative to surgery in the 
management of benign thyroid nodules was first proposed in 
1990, by Livraghi et al. (42). Ethanol acts as a primary sclerosing 
agent (43) promoting cellular dehydration, coagulation necrosis 
and small vessel thrombosis, which is followed by progressive 
fibrosis and nodular volume reduction (18, 44, 45).
This procedure is well established as the first-line option for 
treatment of benign thyroid cysts that recur after evacuation 
(30), and has also been used in solid nodules, particularly in 
patients who are not candidates for surgery or radioiodine 
therapy (2, 32–34, 43).
Perez et al. (2), using PEI, have found a greater mean volume 
reduction in cystic (66.7%) compared to mixed (63%) and solid 
TNs (52.9%). The solid nodules (n = 37) were less likely to com-
pletely respond compared to the others nodules. They have found 
a global satisfactory response in 70% of cases. Nevertheless, it 
was not reported the success rate specifically in solid TNs. 
Furthermore, Lee et al. (34), in a large study with 198 patients, 
demonstrated a relevant reduction in solid TNs in 89% of cases. 
Even though they needed a long follow-up period of 3 years and 
some patients were submitted to six applications, it suggests that 
ethanol ablation still could be a good option to treat solid TNs 
since we achieve a standard protocol. Finally, Bianchini et  al., 
in 2003, treated 26 solid TNs with ethanol injection amount 
according to TNs volume (41). In our protocol, we also used 
ethanol fixed doses, but with shorter periods of re-evaluation 
and consequently more frequent applications. These differences 
contributed to satisfactory success rates, with a larger number of 
patients in a shorter follow-up period.
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When compared to other methods of treatment, PEI has 
shown more effective results and fewer complications. Four 
controlled studies demonstrated a 75–85% success rate after an 
average of two PEI sessions, compared with a 7–38% success rate 
in controls treated by simple cyst evacuation or saline injection 
(46–49). Additionally, a 12-month randomized study evidenced 
that the use of levothyroxine for thyroid stimulating hormone 
(TSH) suppression had no significant effect on nodule reduction, 
while a single PEI session occasionally induces a nearly 50% 
volume reduction (50). Furthermore, Zingrillo et al. (51) demon-
strated a greater nodule volume reduction percentage in patients 
treated with PEI in comparison to radioiodine therapy, which, 
in addition, is accompanied by a 10–40% risk of hypothyroidism 
(51–53). Other therapies have been reported as a good alternative 
to treat solid TNs. Particularly, percutaneous laser ablation and 
radiofrequency have showed good results (54–56). Although 
several studies have demonstrated significant volume reduction 
of thyroid nodules treated with PEI, the protocols proposed are 
a lot heterogeneous in concern to nodules size and type, doses of 
ethanol used, number of injections, intervals between sessions, 
and follow-up length (50, 57, 58).
The highly variable success rate reported in different series 
might be related to the heterogeneous nature of thyroid nodules 
evaluated, ranging from purely cystic to purely solid nodules 
(36). The best results have been obtained in the treatment of 
large or symptomatic cystic nodules. In a prospective study with 
a mean follow-up of 5 years, volume reductions of at least 50% 
were achieved in 40/43 (93%) of patients with cystic nodules 
treated by PEI (39). Del Prete et al. (37) found similar results, 
with volume reduction >50% induced by PEI in 92/98 (94%) 
patients with symptomatic thyroid cysts. Outcomes have been 
reported to be worst in solid TNs, which is likely to be due to 
poor diffusion of ethanol in the solid tissue along with early 
wash out of ethanol due to the increased vascularity of a solid 
nodule as compared to a thyroid cyst (59). Our series included 
patients mixed and solid TNs, which might explain the lower 
success rate of PEI treatment when compared to other authors 
that assessed only simple or complex cysts. Additionally, the 
amount of ethanol to be injected has not been well established, 
with great variability between each protocol (30–100% of the 
initial nodular volume), which might also be related to the dif-
ferent outcomes observed with PEI treatment (2, 33, 38, 46, 47, 
60–62). In the present study, the ethanol dose calculated was 
30% of the nodular volume measured before the beginning of 
each session. Some authors have demonstrated a positive cor-
relation between the volume of ethanol instilled and the volume 
reduction rate of cysts, without an increase of side effects with 
more ethanol injected (38, 59). However, most authors do not 
recommend administering a single dose of more than 10 ml of 
ethanol (63). In our study, we basically adopted a short time 
between evaluations. Therefore, the patients were submitted to a 
higher frequency of applications according to evaluation results. 
It may have contributed to our success rate in a short follow-up 
period compared to other studies.
Percutaneous ethanol injection is a safe procedure without 
serious complications (2). The most common reported adverse 
effects, caused by ethanol leakage into the surrounding tissues 
(63), are local pain, dysphonia, flushing, and dizziness (46, 47, 
49). Although rare, other complications have been reported, such 
as recurrent nerve palsy, Graves’ disease, Graves’ orbitopathy, 
Horner’s syndrome, facial dysesthesia with increased tear flow, 
necrosis of the larynx and skin, and impairment of post-PEI 
surgery due to local fibrosis (57, 64). Accordingly, in our study 
there were no severe or long-standing complications.
In conclusion, our US-guided PEI protocol is safe and effective 
for mixed and solid thyroid nodules when compared with other 
methodologies described, with a 75% success rate, in a short 
follow-up period and no major complications based on that 
new target idea. In addition, we need to increase the number of 
patients to confirm the effectiveness of this approach.
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